Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable Rights Issue. The shortfall was placed to a Japan-based institutional investor at an issue price of A$0.08 per share for a total of A$755,029.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its quarterly cashflow report for the period ending 30 September 2019 (Q1 FY20).
Regeneus Ltd (ASX:RGS) is a Sydney Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell cell-based therapies to address significant unmet medical needs in the human health markets.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received $1.5 million in R&D Tax Incentives from the Australian Tax Office for FY19.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its financial results for the financial year ended 30 June 2019 (FY2019).
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.
Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
